ABO2109 / Suzhou Abogen Biosci - LARVOL DELTA

An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Ruijin Hospital | Trial primary completion date: Jun 2026 ➔ Jun 2028

IO biomarker • Trial primary completion date • Oncology • Solid Tumor

Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Ruijin Hospital

IO biomarker • New P1 trial • Oncology • Solid Tumor